4.0 Article

Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease

期刊

ARCHIVES OF NEUROLOGY
卷 69, 期 10, 页码 1310-1317

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2012.1070

关键词

-

资金

  1. Foundation for the National Institutes of Health
  2. National Institute on Aging [U01 AG024904]
  3. National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health
  4. The Canadian Institutes of Health Research
  5. National Institutes of Health [P30 AG010129, K01 AG030514]
  6. The Dana Foundation

向作者/读者索取更多资源

Background: A blood-based test that could be used as a screen for Alzheimer disease (AD) may enable early intervention and better access to treatment. Objective: To apply a multiplex immunoassay panel to identify plasma biomarkers of AD using plasma samples from the Alzheimer's Disease Neuroimaging Initiative cohort. Design: Cohort study. Setting: The Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project. Participants: Plasma samples at baseline and at 1 year were analyzed from 396 (345 at 1 year) patients with mild cognitive impairment, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control subjects. Main Outcome Measures: Multivariate and univariate statistical analyses were used to examine differences across diagnostic groups and relative to the apolipoprotein E (ApoE) genotype. Results: Increased levels of eotaxin 3, pancreatic polypeptide, and N-terminal protein B-type brain natriuretic peptide were observed in patients, confirming similar changes reported in cerebrospinal fluid samples of patients with AD and MCI. Increases in tenascin C levels and decreases in IgM and ApoE levels were also observed. All participants with Apo epsilon 3/epsilon 4 or epsilon 4/epsilon 4 alleles showed a distinct biochemical profile characterized by low C-reactive protein and ApoE levels and by high cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. The use of plasma biomarkers improved specificity in differentiating patients with AD from controls, and ApoE plasma levels were lowest in patients whose mild cognitive impairment had progressed to dementia. Conclusions: Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B-type brain natriuretic peptide in patients with AD and mild cognitive impairment. Incorporation of plasma biomarkers yielded high sensitivity with improved specificity, supporting their usefulness as a screening tool. The ApoE genotype was associated with a unique biochemical profile irrespective of diagnosis, highlighting the importance of genotype on blood protein profiles.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据